APA (7th ed.) Citation

Xu, J., Zhang, X., Li, Y., Meng, F., Zhang, Y., & Zheng, M. (2025). Efficacy and safety of zanubrutinib combined with chimeric antigen receptor T-cell therapy targeting CD19 in refractory or relapsed diffuse large B cell lymphoma. Cancer Treatment and Research Communications, 43(100902-), . https://doi.org/10.1016/j.ctarc.2025.100902

Chicago Style (17th ed.) Citation

Xu, Jinhuan, Xiaoying Zhang, Yun Li, Fankai Meng, Yicheng Zhang, and Miao Zheng. "Efficacy and Safety of Zanubrutinib Combined with Chimeric Antigen Receptor T-cell Therapy Targeting CD19 in Refractory or Relapsed Diffuse Large B Cell Lymphoma." Cancer Treatment and Research Communications 43, no. 100902- (2025). https://doi.org/10.1016/j.ctarc.2025.100902.

MLA (9th ed.) Citation

Xu, Jinhuan, et al. "Efficacy and Safety of Zanubrutinib Combined with Chimeric Antigen Receptor T-cell Therapy Targeting CD19 in Refractory or Relapsed Diffuse Large B Cell Lymphoma." Cancer Treatment and Research Communications, vol. 43, no. 100902-, 2025, https://doi.org/10.1016/j.ctarc.2025.100902.